Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates

Open access
Pascal, Kristen E, Dudgeon, Drew, Trefry, John C, Anantpadma, Manu, Sakurai, Yasuteru, Murin, Charles D, Turner, Hannah L, Fairhurst, Jeanette, Torres, Marcela, Rafique, Ashique, Yan, Ying, Badithe, Ashok, Yu, Kevin, Potocky, Terra, Bixler, Sandra L, Chance, Taylor B, Pratt, William D, Rossi, Franco D, Shamblin, Joshua D, Wollen, Suzanne E, Zelko, Justine M, Carrion, Ricardo, Worwa, Gabriella, Staples, Hilary M, Burakov, Darya, Babb, Robert, Chen, Gang, Martin, Joel, Huang, Tammy T, Erlandson, Karl, Willis, Melissa S, Armstrong, Kimberly, Dreier, Thomas M, Ward, Andrew B, Davey, Robert A, Pitt, Margaret L M, Lipsich, Leah, Mason, Peter, Olson, William, Stahl, Neil, Kyratsous, Christos A · 2018 · The Journal of Infectious Diseases

Abstract

Background: For most classes of drugs, rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety, and pharmacokinetic profiles. Fully human monoclonal antibodies (mAbs) provide an attractive method to overcome many of these hurdles to rapidly produce therapeutics for emerging diseases. Methods: In this study, we deployed a platform to generate, test, and develop fully human antibodies to Zaire ebolavirus. We obtained specific anti-Ebola virus (EBOV) antibodies by immunizing VelocImmune mice that use human immunoglobulin variable regions in their humoral responses. Results: Of the antibody clones isolated, 3 were selected as best at neutralizing EBOV and triggering FcγRIIIa. Binding studies and negative-stain electron microscopy revealed that the 3 selected antibodies bind to non-overlapping epitopes, including a potentially new protective epitope not targeted by other antibody-based treatments. When combined, a single dose of a cocktail of the 3 antibodies protected nonhuman primates (NHPs) from EBOV disease even after disease symptoms were apparent. Conclusions: This antibody cocktail provides complementary mechanisms of actions, incorporates novel specificities, and demonstrates high-level postexposure protection from lethal EBOV disease in NHPs. It is now undergoing testing in normal healthy volunteers in preparation for potential use in future Ebola epidemics.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiy285

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Emergence of Zaire Ebola Virus Disease in Guinea

    Baize, S., Pannetier, D., Oestereich, L., Rieger, T., Koivogui, L., Magassouba, N., Soropogui, B., Sow, M. S., Keïta, S., De Clerck, H., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1404505 · Cited by 1,366 · cited 2×

    “The Makona strain of EBOV was originally isolated by Dr. Stephan Gunther [20] and was obtained with permission through Dr. Gary Kobinger (Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba).”
    Method

Show all 1 references

Cited by

See all 175

Metadata

Authors
Pascal, K. E., Dudgeon, D., Trefry, J. C., Anantpadma, M., Sakurai, Y., Murin, C. D., Turner, H. L., Fairhurst, J., Torres, M., Rafique, A., Yan, Y., Badithe, A., Yu, K., Potocky, T., Bixler, S. L., Chance, T. B., Pratt, W. D., Rossi, F. D., Shamblin, J. D., Wollen, S. E., Zelko, J. M., Carrion, R., Worwa, G., Staples, H. M., Burakov, D., Babb, R., Chen, G., Martin, J., Huang, T. T., Erlandson, K., Willis, M. S., Armstrong, K., Dreier, T. M., Ward, A. B., Davey, R. A., Pitt, M. L. M., Lipsich, L., Mason, P., Olson, W., Stahl, N., & Kyratsous, C. A.
Venue
The Journal of Infectious Diseases
Published
2018-05-31
Volume
218
Issue
suppl_5
Pages
S612-S626
ISSN
  • 0022-1899 (ISSN-L)
  • 1537-6613
OpenAlex
W2806465206
Cited by
175
References
1
FWCI
15.56
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. https://app.cochat.ai/papers/10.1093/infdis/jiy285
The paper
Pascal, K. E., Dudgeon, D., Trefry, J. C., Anantpadma, M., Sakurai, Y., Murin, C. D., Turner, H. L., Fairhurst, J., Torres, M., Rafique, A., Yan, Y., Badithe, A., Yu, K., Potocky, T., Bixler, S. L., Chance, T. B., Pratt, W. D., Rossi, F. D., Shamblin, J. D., . . . Kyratsous, C. A. (2018). Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiy285

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.